Researchers at the University of California, Davis have developed isolated peptides that selectively bind M1 and M2 macrophages to enable precise diagnosis and targeted treatment of macrophage-associated diseases, including cancer.

Researchers at the University of California, Davis have developed an advancement in the field of healthcare technology, specifically in the development and application of silyl lipids for RNA vaccines.

Researchers at the University of California, Davis have developed a potential therapeutic strategy aiming at disrupting intercellular communication of pathogens using quorum sensing molecules and silicon-based pharmacophores.

Researchers at the University of California, Davis have developed a therapeutic use of cannabinoids for the treatment of Neurodegenerative Disorders (NDDs).

Researchers at the University of California, Davis have developed a nanoparticle system combining photothermal therapy and chemotherapy for enhanced cancer treatment.

Researchers at the University of California, Davis have developed non-invasive methods for intranasally delivering the drug allopregnanolone.

Researchers at the University of California, Davis and the Chiba University Center for Forensic Mental Health in Japan have collaborated to develop an enzyme inhibitor that prevents the onset of neurodevelopmental disorders.

Researchers at the University of California, Davis have developed a therapeutic approach to prevent and treat cancer cachexia by inhibiting soluble epoxide hydrolase, promoting resolution of systemic inflammation, mitigating muscle wasting, and improving survival outcomes in preclinical models without inducing toxicity or immunosuppression.

Researchers at the University of California, Davis have developed a technology that introduces an approach to creating semi-living, non-replicating cellular systems for advanced therapeutic applications.

Researchers at the University of California, Davis, have developed a method to prepare chemically well-defined HSA-drug conjugates, such that ligation can occur in vitro or in vivo under physiological condition.

Researchers at the University of California, Davis have developed a novel stem cell gene therapy approach utilizing a modified SYNGAP1 protein to treat Synaptic Ras GTPase Activating Protein 1-related intellectual disability (SRID).

Brief description not available

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed novel antisense oligonucleotide (ASO) therapies that enhance ADNP protein expression to address haploinsufficiency in ADNP syndrome.

Transcranial focused ultrasound stimulation (TFUS) is a neuromodulation method that aims to change nervous tissue activity non-invasively. TFUS may be applied in an MRI scanner using image-based navigation. There is evidence in animals that the presence of a magnetic field may change the effects of TFUS on brain activity, presumably via Lorentz force effects. The evidence for any such effect in humans is weak and it is usually assumed that the MRI magnetic field does not alter the action of the TFUS. UC investigators provide a new method, Faraday induction-enhanced Focused Ultrasound Stimulation (FIEFUS), of applying ultrasound to nervous tissue (central or peripheral) by utilizing the strong, fringe magnetic field gradients found outside an MRI scanner. The concept is based on the theoretical generation of substantial electromagnetic induction from ultrasound-induced motions within the strong static magnetic field gradient, which could then be used to affect nervous tissue activity. This approach is motivated by the observation that a static, homogeneous magnetic fieldmayalter TFUS effects in animals—possibly through Lorentz forces—suggesting a strong magnetic field gradient could be a controllable experimental variable to induce circulating electric fields localized to an ultrasound target region.

Chronic wounds affect over 6.5 million people in the United States costing more than $25B annually. 23% of military blast and burn wounds do not close, affecting a military patient's bone, skin, nerves. Moreover, 64% of military trauma have abnormal bone growth into soft tissue. Slow healing of recalcitrant wounds is a known and persistent problem, with incomplete healing, scarring, and abnormal tissue regeneration. Precise control of wound healing depends on physician's evaluation, experience. Physicians generally provide conditions and time for body to either heal itself, or to accept and heal around direct transplantations, and their practice relies a lot on passive recovery. And while newer static approaches have demonstrated enhanced growth of non-regenerative tissue, they do not adapt to the changing state of wound, thus resulting in limited efficacy.

Researchers at the University of California, Davis have engineered dominant negative CD40L mutant polypeptides that inhibit CD40/CD40L-mediated signaling, offering therapeutic potential for inflammatory, immune disorders, and cancer with improved safety profiles.

POEM is a groundbreaking 3D bioprinting technology enabling high-resolution, multi-material, and cell-laden structure fabrication with enhanced cell viability.

This technology offers a novel approach to treating epilepsy by preventing the spread of epileptic networks and improving memory deficits through targeted electrical stimulation.

A revolutionary method for improving the efficiency and quality of reprogramming adult cells into stem cells or other therapeutically relevant cell types via adhesome gene manipulation.

This technology represents a groundbreaking approach to treating Primary Open Angle Glaucoma by directly targeting the trabecular meshwork pathology with lipid nanoparticle-mediated delivery of gene editing tools or anti-sense oligos.

Researchers at the University of California, Davis have developed technology that provides an advanced system for monitoring and supporting patient resuscitation and mechanical ventilation, enhancing clinical decision-making.

A novel approach to significantly enhance vancomycin's effectiveness against drug-resistant pathogens by conjugating it with a minimal teixobactin pharmacophore.

Innovative cell lines enabling precise genetic modifications to advance research in gene function, disease modeling, and potential therapeutic interventions.